When a hospital, clinic, or other provider is reimbursed less for a brand-name drug than it paid to acquire and administer it, the shortfall can become a financial loss for the provider—and a cost pressure for patients, employers, insurers, and taxpayers. This is known as negative drug reimbursement or, in some settings, a negative margin. It is not a universal feature of brand-name medicines: the outcome depends on the drug, payer, contract, site of care, and reimbursement rules. Medicare data illustrate the stakes: in 2023, Medicare Part B drug spending reached about $43 billion before beneficiary cost sharing, according to the Medicare Payment Advisory Commission. Understanding acquisition costs, reimbursement formulas, and the incentives behind them helps explain why a provider’s loss can ripple through the health system.
Provider drug reimbursement and the acquisition-cost gap
Provider drug reimbursement is the payment a health plan or public program makes for a medicine and, depending on the setting, its administration. The acquisition-cost gap is the difference between what a provider actually pays to obtain a drug and what it receives for the drug itself. The American Society of Clinical Oncology (ASCO) describes the buy-and-bill model as a system in which a physician practice purchases and stores a drug, administers it, and then seeks reimbursement from the payer.
A negative margin occurs when drug reimbursement falls below the provider’s acquisition and related costs. The calculation is not always as simple as comparing a published price with a payment rate: providers may receive discounts or rebates, while also bearing expenses for handling, storage, billing, staff, and administration. The key characteristics are therefore the drug’s net purchase cost, the payer’s reimbursement method, the time between purchase and payment, and the cost of delivering treatment.
Buy-and-bill reimbursement
Buy-and-bill means a provider buys a drug upfront and later bills the patient’s insurer for the medicine and its administration. The practice takes on inventory and payment risk: it must pay suppliers before knowing exactly how much the payer will allow or when the claim will be settled. The model is common for infused or injected medicines delivered in physician offices and hospital outpatient departments.
Medicare Part B generally pays for separately payable physician-administered drugs using a formula based on the drug’s average sales price (ASP), with an additional percentage intended to help cover handling and related expenses. The Centers for Medicare & Medicaid Services (CMS) describes the standard statutory formula as ASP plus 6%; because of federal budget sequestration, the effective add-on has generally been 4.3% since 2013. This add-on is not a guarantee of profit. If a provider’s actual net acquisition cost is higher than the payment, or the add-on does not cover other costs, the drug may still have a negative margin.
Negative reimbursement and negative margin
Negative reimbursement usually refers to payment that does not cover a provider’s drug acquisition expense; negative margin is broader, because it can include administration and operating costs. A drug may be reimbursed above its invoice price yet still produce a negative total margin after discounts, staffing, wastage, and billing costs are considered. Conversely, a provider’s confidential purchase discount may make the net margin positive even when a public benchmark suggests a shortfall.
The distinction matters when discussing brand-name drugs. A brand medicine is not automatically unprofitable for the provider, and a reported loss on one drug does not establish that every provider or payer experiences the same result. The relevant comparison is the provider’s net cost against the payment it can collect under its particular contract and care setting.
Why brand-name drug margins can turn negative
A reimbursement shortfall can emerge when the payment benchmark moves differently from the provider’s purchase price. ASP is calculated from manufacturer sales data and reflects certain price concessions, but a provider may pay a different amount because of wholesaler terms, purchasing arrangements, distribution fees, or timing. A formula tied to an average cannot guarantee that every individual practice’s acquisition cost will fall below the allowed payment.
Price changes, discounts, and payment timing
Drug prices and reimbursement benchmarks do not necessarily adjust at the same moment. A provider may purchase inventory at one price and later be paid using a benchmark based on an earlier reporting period. If the benchmark or payer allowance declines before the provider’s inventory is used, the practice can be left with a mismatch. Discounts and rebates can reduce the final cost, but they may be delayed, conditional, or unavailable to a particular provider.
The U.S. Department of Health and Human Services Office of Inspector General has documented how Medicare Part B reimbursement can exceed or fall below provider acquisition costs, depending on the drug and the relationship between ASP and reported acquisition data. Such comparisons are evidence that payment benchmarks and purchase costs can diverge; they do not, by themselves, show the net margin of every individual provider.
Payer contracts and site-of-care differences
Commercial insurers, Medicare, and Medicaid may use different payment terms, formularies, and authorization rules. A commercial contract may specify a percentage of a benchmark, a fixed rate, or another negotiated amount. Medicaid payment rules vary by state and program. Hospital outpatient departments and independent physician offices can also face different overhead, purchasing arrangements, and payer contracts.
As a result, a medicine that loses money in one clinic may have a positive margin elsewhere. Providers may also face claim denials, prior-authorization delays, patient eligibility changes, or payment delays, which increase the financial risk of carrying expensive inventory. These factors are especially relevant for high-cost specialty medicines and drugs administered repeatedly over a course of treatment.
Administration and inventory costs
Drug reimbursement is not the same as payment for the full treatment encounter. Providers may need to maintain temperature-controlled storage, prepare doses, monitor patients, manage waste, and employ clinical and billing staff. Some of these services may be billed separately, but payment may not fully match the actual cost or may be bundled into another payment. A partially used vial or a dose that must be discarded can add expense without producing a corresponding drug payment.
The Medicare Payment Advisory Commission (MedPAC) tracks Part B drug spending and payment policy because physician-administered medicines represent a substantial and growing area of Medicare expenditure. MedPAC reported approximately $43 billion in Medicare Part B drug spending in 2023, before beneficiary cost sharing. That system-wide figure does not measure provider losses, but it shows why small differences in payment and acquisition costs can matter across a large, high-cost market.
How provider losses can affect patients and the wider system
A provider’s loss does not automatically become a patient’s bill or an insurer’s immediate surcharge. The consequences depend on contracts, regulations, and the provider’s ability to absorb or offset the loss. Still, repeated shortfalls can influence where care is offered, which services a practice can sustain, and how health systems negotiate prices and reimbursement.
Access to care and treatment location
If a practice cannot reliably cover the cost of stocking a medicine, it may limit the drugs it keeps on hand, refer patients to another site, or decide that a service is financially unsustainable. This risk can be more consequential in rural or underserved areas, where patients have fewer alternative clinics and travel to a hospital or infusion center may be difficult. A reimbursement shortfall is only one possible reason for such decisions, so it should not be treated as proof that a particular drug has been withdrawn from care.
Site-of-care changes can affect patients’ travel, scheduling, and continuity of treatment. They can also shift costs between settings rather than eliminate them. When evaluating access, policymakers and providers need to distinguish a genuine supply or financial barrier from a change in location that preserves treatment but alters who delivers it.
Costs for insurers, employers, and taxpayers
Providers may try to offset losses through negotiations, changes to service mix, or reductions in other operating expenses. Insurers and employers may face pressure to renegotiate contracts or alter coverage, while public programs must balance access with budget stewardship. These effects are not automatic pass-throughs: the final distribution of costs depends on the market and the terms of payment.
The broader issue is that drug spending and provider payment are connected but not identical. A high drug price can increase payer spending even when a provider’s margin is small or negative. Likewise, a provider’s positive margin does not establish that the drug is affordable for patients or the health system. Separating the manufacturer’s price, the provider’s net acquisition cost, the payer’s allowed amount, and the patient’s cost sharing is essential to understanding who bears which cost.
A practical example of the reimbursement gap
Consider a clinic that buys a dose of a brand-name infusion drug for $1,000 after its available purchasing discounts. Its payer allows $980 for the drug, and the clinic incurs additional costs to store, prepare, and administer it. The clinic has a $20 shortfall on the drug before those other costs are counted, so its total treatment margin is more negative still unless separate payments or other savings cover the difference. Another clinic could pay less for the same dose or have a different contract and therefore reach a different result. This simplified example illustrates the mechanism; it is not a claim about a specific medicine or actual market price.
What policymakers and providers can do
Reducing avoidable losses requires better visibility into the components of payment and cost, rather than assuming that one reimbursement formula works equally well for every provider and medicine. Any reform must also consider incentives: payment should support reliable access and efficient care without rewarding unnecessarily high drug prices or encouraging treatment in a more expensive setting.
Improve cost and payment transparency
Providers and payers can monitor acquisition costs, reimbursement, denials, wastage, and administrative expenses at the drug and site-of-care level. Clearer reporting can identify where a benchmark consistently falls below reasonable costs and whether the problem stems from purchase price, contract design, delayed payment, or operational expense. Confidential rebates and discounts should be considered carefully so that reported figures reflect net costs as accurately as possible.
Review payment incentives and contract design
Public agencies and private plans can assess whether payment methods keep pace with market changes while preserving safeguards against excessive spending. Contract terms can clarify how price benchmarks are updated, how wastage is handled, and how quickly providers are paid. Policymakers should evaluate effects on small practices and underserved communities as well as on large health systems.
Support informed patient and provider decisions
Patients can ask their care team whether a recommended medicine is covered, what out-of-pocket costs may apply, and whether an alternative treatment or site of care is clinically appropriate. Providers can explain coverage and financial-assistance options without allowing reimbursement considerations to substitute for clinical judgment. Further reading from CMS, MedPAC, ASCO, and the HHS Office of Inspector General can help readers understand the rules and evidence relevant to their own care setting.
Conclusion: provider losses are a system-wide warning, not a universal outcome
When reimbursement for a brand-name drug falls below a provider’s net acquisition and delivery costs, the result can be a negative margin. Buy-and-bill practices face particular exposure because they purchase inventory upfront, while ASP-based Medicare payment, commercial contracts, price timing, discounts, and administration costs all shape the final outcome. The roughly $43 billion in Medicare Part B drug spending reported for 2023 underscores the scale of the market, but it does not mean every provider loses money.
The wider implications include possible pressure on access, treatment location, and negotiations among providers, payers, and manufacturers—but the burden is not passed on in a simple or automatic way. Better cost transparency, careful payment design, and attention to local access can help policymakers identify genuine reimbursement gaps. Patients and providers should review coverage and treatment options together, while decision-makers should examine drug-level and site-specific evidence before drawing conclusions about who ultimately pays.
Sources: Medicare Payment Advisory Commission, “Chapter 10: Medicare Part B Drug Payment Policy,” March 2025, https://www.medpac.gov/document/march-2025-report-to-the-congress-medicare-payment-policy/; Centers for Medicare & Medicaid Services, “Medicare Part B Drug Average Sales Price,” https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files; American Society of Clinical Oncology, “The Economics of Cancer Care,” https://www.asco.org/practice-patients/patient-care-and-research/economics-cancer-care; U.S. Department of Health and Human Services Office of Inspector General, “Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2021 Average Sales Prices,” https://oig.hhs.gov/reports/all/2023/medicare-part-b-drug-payments-impact-of-price-substitutions-based-on-2021-average-sales-prices/
